Skip to content

US · NXGLW · MEDICAL - INSTRUMENTS & SUPPLIES

NEXGEL, Inc. (NXGLW) intrinsic value and stock valuation

$0.12as of 2026-09-18 · Mkt cap 1.1M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NEXGEL, Inc. DCF and intrinsic value

InvestorsCraft values NXGLW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NXGLW’s statements →

NEXGEL, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Langhorne, PA, US nexgel.com

How the business is doing

Fiscal 2025–2016, USD

Revenue
$2.15T+6.8% 5y CAGRd
20252016
Net income
-$-1.78T
20252016
Free cash flow
-$-1.32T
20252016
Total equity
$794B-42% 5y CAGRd
20252016

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2016, USD
FYFYFYFYFY
Revenue$11.4T$8.69T$4.09T$2.05T$1.55T
Operating income-$-3.35T-$-3.55T-$-3.48T-$-3.35T-$-2.57T
Net income-$-3T-$-3.28T-$-3.16T-$-4.75T-$-4.31T
EPSd-$-381.96K-$-503.87K-$-556.61K-$-851.33K-$-773.48K
Operating cash flow-$-1.31T-$-3.87T-$-3.24T-$-2.99T-$-2.75T
Capital expenditure-$-68B-$-443B-$-696B-$-96B-$-269B
Free cash flow-$-1.38T-$-4.31T-$-3.93T-$-3.09T-$-3.02T
Total assets$10.5T$11T$9.96T$10.4T$17T
Total debt$3.09T$2.83T$2.8T$2.08T$4.26T
Net debt$2.77T$1.02T$98B$982B-$-9.09T
Total equity$4.89T$6.08T$5.17T$7.64T$12.1T
Cash and short-term investments$317B$1.81T$2.7T$6.61T$13.4T
Income statement
FYFYFYFYFY
Revenue$11.4T$8.69T$4.09T$2.05T$1.55T
Cost of revenue$6.91T$5.94T$3.72T$1.79T$1.54T
Gross profit$4.51T$2.75T$374B$256B$8B
Research and development expenses$2B$78B$103B$367B$31B
Selling, general and administrative expenses$7.86T$5.91T$3.4T$2.82T$2.41T
Other expenses$0.00$313B$350B$421B$142B
Operating expenses$7.86T$6.3T$3.85T$3.6T$2.58T
Cost and expenses$14.8T$12.2T$7.57T$5.4T$4.12T
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$34B$81B$15B$1.34T$2T
Depreciation and amortization$740B$480B$443B$301B$138B
Ebitda-$-2.12T-$-2.9T-$-2.73T-$-3.11T-$-2.17T
Operating income-$-3.35T-$-3.55T-$-3.48T-$-3.35T-$-2.57T
Total other income/expenses, net$459B$91B$289B-$-1.4T-$-1.74T
Income before tax-$-2.89T-$-3.46T-$-3.19T-$-4.75T-$-4.31T
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3T-$-3.28T-$-3.16T-$-4.75T-$-4.31T
Weighted average shares outstanding$7.85T$6.51T$5.67T$5.57T$5.57T
Weighted average diluted shares outstanding$7.85T$6.51T$5.67T$5.57T$5.57T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$317B$1.81T$2.7T$6.61T$13.4T
Net receivables$673B$933B$633B$222B$209B
Inventory$2.11T$1.75T$1.32T$502B$291B
Total current assets$4.34T$5.11T$5.05T$7.51T$13.9T
Property, plant and equipment, net$3.97T$3.84T$3.35T$2.46T$2.65T
Goodwill and intangible assets$1.81T$1.94T$1.45T$331B$344B
Long-term investments$249B$0.00$0.00$0.00$0.00
Total non-current assets$6.12T$5.87T$4.9T$2.85T$3.06T
Total assets$10.5T$11T$9.96T$10.4T$17T
Accounts payable$1.29T$1.29T$1.23T$265B$254B
Short-term debt$474B$393B$558B$222B$2.25T
Deferred revenue$2B$179B$20B$0.00$54B
Total current liabilities$2.96T$2.47T$2.55T$859B$2.89T
Long-term debt$2.61T$2.43T$2.24T$1.86T$2.01T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.61T$2.43T$2.24T$1.86T$2.01T
Capital lease obligations$2.5T$2.14T$1.96T$1.8T$1.95T
Total liabilities$5.57T$4.9T$4.79T$2.72T$4.9T
Common stock$8B$8B$6B$6B$6B
Retained earnings-$-21T-$-18T-$-14.72T-$-11.56T-$-6.81T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$4.89T$6.08T$5.17T$7.64T$12.1T
Total investments$249B$0.00$0.00$5.51T$0.00
Total debt$3.09T$2.83T$2.8T$2.08T$4.26T
Net debt$2.77T$1.02T$98B$982B-$-9.09T
Cash flow statement
FYFYFYFYFY
Net income-$-2.89T-$-3.28T-$-3.16T-$-4.75T-$-4.31T
Depreciation and amortization$740B$478B$443B$301B$113B
Stock-based compensation$654B$367B$217B$298B$285B
Change in working capital$468B-$-1.17T-$-421B-$-234B-$-593B
Accounts receivable$260B-$-300B-$-411B-$-13B-$-137B
Inventory-$-360B-$-432B-$-760B-$-211B-$-58B
Accounts payable-$-3B$182B$968B$11B-$-405B
Net cash provided by operating activities-$-1.31T-$-3.87T-$-3.24T-$-2.99T-$-2.75T
Investments in property, plant and equipment-$-68B-$-443B-$-696B-$-96B-$-269B
Acquisitions, net$0.00-$-400B-$-547B$96B$0.00
Net cash used for investing activities-$-68B-$-775B$4.46T-$-5.6T-$-269B
Common stock issued$963B$3.77T$0.00$0.00$13.5T
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$630B$3.75T$379B-$-3.66T$16.3T
Net change in cash-$-749B-$-893B$1.6T-$-12.25T$13.3T
Cash at end of period$1.06T$1.81T$2.7T$1.1T$13.4T
Operating cash flow-$-1.31T-$-3.87T-$-3.24T-$-2.99T-$-2.75T
Capital expenditure-$-68B-$-443B-$-696B-$-96B-$-269B
Free cash flow-$-1.38T-$-4.31T-$-3.93T-$-3.09T-$-3.02T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NEXGEL, Inc.

        NEXGEL, Inc. is a company that manufactures specialized hydrogels and gels, notable for their high water content, electron beam cross-linking, and aqueous polymer base. These advanced materials are widely utilized across several sectors, including wound care, medical diagnostics, transdermal drug delivery systems, and various cosmetic applications. Their diverse product portfolio features items such as facial masks, under-eye patches, blister-shielding foot care, hexagel, cracked heel repair patches, and cooling fever patches. Originally known as AquaMed Technologies, Inc., the company officially adopted the name NEXGEL, Inc. in November 2019. Founded in 1997, its operations are headquartered in Langhorne, Pennsylvania.

        CEO
        Brian J. Kieser
        Employees
        19
        Beta
        0.77

        Explore

        Frequently asked questions

        What is the intrinsic value of NEXGEL, Inc. (NXGLW)?

        InvestorsCraft does not currently publish an intrinsic value for NXGLW. How the IC value is calculated.

        Is NXGLW undervalued?

        InvestorsCraft does not publish an undervaluation signal for NXGLW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.